Volume 18, Number 3—March 2012
Letter
Adherence to Oseltamivir Guidelines during Influenza Pandemic, the Netherlands
Esther H. Fietjé, Daphne Philbert
, Erica C.G. van Geffen, Nina A. Winters, and Marcel L. Bouvy
, Erica C.G. van Geffen, Nina A. Winters, and Marcel L. Bouvy
Table
Reported risk factors of patients with and without influenza symptoms who were dispensed a prescription for oseltamivir, the Netherlands, 2009–10
| Risk factor | No. (%) patients* |
||
|---|---|---|---|
| Total, n = 300 | Influenza symptoms, n = 223 | No influenza symptoms, n = 77 | |
| Chronic condition | 211 (70.3) | 154 (69.1) | 57 (74.0) |
| Chronic respiratory disease | 127 (42.3) | 98 (43.9) | 29 (37.7) |
| Lower immune resistance caused by illness or medical treatment | 76 (25.3) | 50 (22.4) | 26 (33.8) |
| Cardiovascular disease | 52 (17.3) | 34 (15.2) | 18 (23.4) |
| Diabetes | 44 (14.7) | 28 (12.6) | 16 (20.8) |
| Renal disease | 10 (3.3) | 5 (2.2) | 5 (6.5) |
| Other | 125 (41.7) | 86 (38.6) | 39 (50.6) |
| Age >60 y | 66 (22.0) | 35 (15.7) | 31 (40.3) |
| Age <2 y | 36 (12.0) | 35 (15.7) | 1 (1.3) |
| Regular patient contact by health care worker | 22 (7.3) | 15 (6.7) | 7 (9.1) |
| Pregnancy | 5 (1.7) | 2 (0.9) | 3 (3.9) |
| No. risk factors | |||
| 0 | 44 (14.7) | 34 (15.2) | 10 (13.0) |
| 1 | 137 (45.7) | 111 (49.8) | 26 (33.8) |
| 2 | 72 (24.0) | 53 (23.8) | 19 (24.7) |
| >3 | 47 (15.7) | 25 (11.2) | 22 (28.6) |
*Percentages may total >100% because of rounding.
Page created: February 16, 2012
Page updated: February 16, 2012
Page reviewed: February 16, 2012
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.